Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Entecavir

FDA-approved product (tablet, oral), marketed as Baraclude, Entecavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Entecavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF10; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Entecavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Entecavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

    NCT01026610 · start 2009-08

    Registered record
    Registry ID
    NCT01026610
    Conditions
    Chronic Hepatitis B
    Interventions
    LB80380 90 mg; LB80380 150 mg; entecavir 0.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-08
    Completion
    2011-05
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionLB80380 90 mg; LB80380 150 mg; entecavir 0.5 mg
    PhasePhase 2
    Registry statusCompleted

  • The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure

    NCT01254994 · start 2007-08

    Registered record
    Registry ID
    NCT01254994
    Conditions
    Liver Failure
    Interventions
    entecavir; Traditional comprehensive medical treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2010-12
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Failure
    Interventionentecavir; Traditional comprehensive medical treatment
    PhasePhase 2
    Registry statusCompleted

  • A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

    NCT00393484 · start 2007-02

    Registered record
    Registry ID
    NCT00393484
    Conditions
    Chronic Hepatitis B
    Interventions
    Entecavir; Lamivudine Placebo; Lamivudine; Entecavir Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2013-09
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionEntecavir; Lamivudine Placebo; Lamivudine; Entecavir Placebo
    PhasePhase 4
    Registry statusCompleted

  • Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B

    NCT00921180 · start 2007-02

    Registered record
    Registry ID
    NCT00921180
    Conditions
    Hepatitis B, Chronic
    Interventions
    Entecavir and peginterferon alfa-2a; Placebo and peginterferon
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-02
    Completion
    2013-12
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionEntecavir and peginterferon alfa-2a; Placebo and peginterferon
    PhasePhase 4
    Registry statusUnknown

  • Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

    NCT00096785 · start 2004-12

    Registered record
    Registry ID
    NCT00096785
    Conditions
    Hepatitis B; Chronic Disease
    Interventions
    entecavir; adefovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-12
    Completion
    2008-04
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Chronic Disease
    Interventionentecavir; adefovir
    PhasePhase 3
    Registry statusCompleted